TIDMOPTI
RNS Number : 9002Q
OptiBiotix Health PLC
01 July 2022
OptiBiotix Health plc
("OptiBiotix", the "Group" or the "Company")
Director Appointment and Director Dealing
OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d
eveloping compou n ds to tackle obesity, high cholesterol, diabetes
and skin care, a nnounces the appointment of René Kamminga as a
Director of the Company, with immediate effect and issue of options
as part of his appointment. René is currently a Director and Chief
Executive Officer of OptiBiotix Ltd, the Company's wholly owned
prebiotic business.
Director appointment
René has more than 25 years' experience in the sale of
speciality ingredients and products and joined OptiBiotix Ltd in
March 2021 (RNS: 23 March 2021) from the position of Vice President
of Business Development and Chief Commercial Officer of the
Nutraceuticals division of one of the world's largest Omega-3 and
fish oil refiners KD Pharma Group. As Chief Commercial Officer,
René was integral in developing and delivering on a strategy of
moving the business from bulk ingredients to finished product
solutions. Prior to joining KD Pharma, René was President of Kerry
Groups Texturants division with full P&L responsibility for its
speciality ingredient business in Europe. Prior to this he worked
in business director roles for Quest and Uniqema, subsidiaries of
Unilever and ICI.
Since his appointment to OpiBiotix Ltd, René has brought
experience of developing a business from selling bulk ingredients
to finished product and a wealth of industry contacts in both the
pharmaceutical and nutraceutical industries. He has a strong track
record of rapidly growing sales and has been involved in a number
of acquisitions in support of accelerating business growth. His
experience of speciality food ingredients and high value final
product solutions will help drive the business expansion of
OptiBiotix' growing pipeline of microbiome modulation products and
technologies.
René's appointment is part of a long-planned strategy to appoint
experienced industry business leaders to lead each part of the
business allowing the Group CEO to focus on identifying and
developing new technologies and acquisition opportunities. His
appointment to the main Board is recognition of the progress he has
made in building OptiBiotix's prebiotic business.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
René Kamminga (aged 55):
Current Directorships Directorships in the past
five years
OptiBiotix Limited Kamminga Ventures BV
--------------------------
Alsoka BV
--------------------------
Kamminga Beheer BV
--------------------------
Care by Nature BV
--------------------------
René Kamminga currently holds 55,844 shares in the Company,
representing 0.06 per cent. of the Company's current issued share
capital and options over 500,000 ordinary shares in the Company as
part of the issue of options detailed below.
There is no further information regarding René required to be
disclosed under the AIM Rules.
Director dealing and issue of options
As part of the OptiBiotix Share Option Plan, options over
500,000 new ordinary shares have been granted to René Kamminga (the
"Options"). The Options are exercisable within 10 years at an
exercise price of 2p per share, which will be subject to a
combination of performance and time-based vesting criteria.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
welcome René onto the Company's main Board in recognition of
progress he has made in building OptiBiotix's prebiotic business as
CEO of OptiBiotix Ltd. René's experience and track record of
growing sales and network of industry contacts within the
ingredients and nutraceutical industries will bring sector specific
expertise to the Board and support continued growth in this
exciting area of healthcare."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.]
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------------------------
a. Name René Kamminga
---------------------------------------- ----------------------------------------------------
2 Reason for notification
---------------------------------------- ----------------------------------------------------
a. Position/Status Director
---------------------------------------- ----------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---------------------------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
---------------------------------------- ----------------------------------------------------
b. LEI 213800UKYQFT941QHS14
---------------------------------------- ----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------------------------
a. Description of Options over ordinary shares of 2p each
the financial
instrument, type
of instrument
ISIN: GB00BP0RTP38
Identification
Code
---------------------------------------- ----------------------------------------------------
b. Nature of the Issue of options over 500,000 ordinary shares
transaction as part of the Company Share Options Plan
---------------------------------------- ----------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
---------------------------------------- ----------------------------
2p 500,000
---------------------------- ------------------
d. Aggregated information
* Volume N/A
* Price
---------------------------------------- ----------------------------------------------------
e. Date of the transaction 1 July 2022
---------------------------------------- ----------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
---------------------------------------- ----------------------------------------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHWPUACQUPPGAU
(END) Dow Jones Newswires
July 01, 2022 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
